Hormonal Contraceptive Market Size, Share & Trends Analysis Report By Method (IUDs, Pills, Implants), By Hormone (Combination Hormonal Contraceptives, Progestin-only), By Region, And Segment Forecasts, 2022 - 2030

Hormonal Contraceptive Market Growth & Trends

The global hormonal contraceptive market size is expected to reach USD 24.2 billion by 2030, based on a new report by Grand View Research, Inc. It is projected to register a CAGR of 4.29% during the forecast period. The introduction of innovative products and growing awareness about reproductive & sexual health in emerging regions are likely to drive the growth. An increasing number of women in developing economies are using contraceptives due to the rise in government initiatives and programs. This factor is anticipated to accelerate market growth. For instance, according to the UN World Fertility and Family Planning 2020, in 2019, 49% of the women of reproductive age received some form of contraception to avoid pregnancy with 91% of women among them using modern contraceptive methods including implants, patches, IUDs, and others.

According to the State of World Population 2022, by UNFPO, globally, approximately 50% of all 121 million pregnancies each year are unwanted. As per the Seeing, the Unseen: The case for action in the neglected crisis of unintended pregnancy, more than 60% of unwanted pregnancies result in abortion and the projected 45% among them are unsafe. Hence, to avoid unsafe abortions, countries are spreading awareness about contraceptives, which is expected to propel industry growth. The IUD segment is expected to witness the fastest growth during the forecast period due to the entry of new devices, the availability of long-acting reversible birth control methods, and more than 99.0% effectiveness.

The COVID-19 pandemic has significantly impacted the industry owing to supply chain disruptions and a decline in family planning numbers. Contraceptive manufacturers, such as Merck & Co., have reported reduced demand for the contraceptive implant, Nexplanon, due to the prioritization of COVID-19 patients by healthcare providers. The industry is fragmented owing to the introduction of various generic drugs. For instance, in December 2019, Prasco, in collaboration with Merck & Co., Inc., launched the generic version of the NuvaRing, a vaginal ring containing ethinylestradiol.

Hormonal Contraceptive Market Report Highlights

• High demand for contraceptive methods can be attributed to the rising awareness about pills & devices, the significance of family planning, and the presence of supportive government policies improving access to these products
• By hormone, the combination hormonal contraceptive segment held the largest share in 2021 owing to the fewer side effects and lower chances of developing acne and related symptoms
• Based on method, pills accounted for the largest share in 2021 as these products are convenient to use and exhibit more than 99.0% effectivity when accurately consumed
• Furthermore, the ease of availability, fewer adverse effects, and the presence of a large number of players contribute to the segment growth
• North America held the largest share in 2021 and is anticipated to maintain its dominance during the forecast period due to the presence of major market players, high per capita income, and supportive government initiatives
• The Asia Pacific is estimated to witness the fastest CAGR from 2022 to 2030 due to high unmet needs, an expected increase in coverage in the next 15 years, and an increasing number of women in their reproductive age